Riskpilot← Back to searchSign inGet full accessPHARMACOSMOS A/S
A/SActiveCVR 15517085Rørvangsvej 30Manufacture of pharmaceutical preparations · NACE 2120Est. 1991314 employees
Revenue 2025
DKK 2,6B
+63% vs 2024
EBITDA margin
89.9%
+247% vs 2024
Equity ratio
46.5%
Financial strength
Net profit 2025
DKK 1,6B
+105% vs 2024
| Revenue | DKK 2,6B | +63% |
| EBITDA | DKK 2,4B | +247% |
| Net profit | DKK 1,6B | +105% |
| Total assets | DKK 4,7B | +78% |
| Equity | DKK 2,2B | +34% |
| Employees | 314 | — |
Legal name
PHARMACOSMOS A/S
CVR number
15517085
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1. oktober 1991
Share capital
DKK 101.000.000
Employees
314 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse, eller af et medlem af
direktionen og et medlem af bestyrelsen i forening, eller af Tobias Sidelmann Christensen.
Company purpose
Selskabets formål er at drive fabrikation og virksomhed i forbindelse hermed
Address
Rørvangsvej 30
Phone
+4559485959
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 257.990 | 109.910 | 208.822 | 448.039 | 616.747 | 613.893 | 713.209 | 748.670 | 782.207 | 876.811 | 1.104.166 | 1.613.141 | 2.623.000 |
| Staff expenses | -0 | -81.340 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -233.000 |
| EBITDA | 171.879 | 13.171 | 104.797 | 134.007 | 267.962 | 196.137 | 204.411 | 210.383 | 219.335 | 212.086 | 272.231 | 679.525 | 2.359.000 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -72.423 | -69.058 | -92.798 | -118.319 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 171.879 | 13.171 | 104.797 | 134.007 | 195.539 | 127.079 | 111.613 | 92.064 | 219.335 | 212.086 | 272.231 | 679.525 | 2.359.000 |
| Net financials | -15.027 | -12.430 | -3.200 | -4.211 | 22.160 | -35.722 | 28.583 | -48.536 | -316.944 | 19.066 | -111.045 | 59.196 | -646.000 |
| Profit before tax | 156.852 | 741 | 101.598 | 129.795 | 206.361 | 91.357 | 128.427 | 89.282 | -97.609 | 231.152 | 165.916 | 1.038.911 | 2.225.000 |
| Tax | 41.402 | -5.428 | 20.455 | 27.102 | 47.646 | 22.232 | 26.359 | 32.825 | 38.396 | 61.114 | 51.642 | 249.210 | 603.000 |
| Net profit | 115.451 | 6.169 | 81.143 | 102.694 | 158.715 | 69.125 | 102.068 | 56.457 | -136.005 | 170.038 | 114.274 | 789.701 | 1.622.000 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 744.717 | 629.789 | 740.155 | 790.669 | 966.772 | 1.161.615 | 1.300.417 | 1.344.417 | 1.450.673 | 1.590.166 | 1.753.450 | 2.657.695 | 4.723.000 |
| Equity | 435.316 | 394.791 | 496.887 | 547.743 | 656.757 | 720.762 | 826.960 | 884.049 | 642.802 | 807.467 | 854.594 | 1.635.784 | 2.197.000 |
| Long-term debt | 129.430 | 112.898 | 95.958 | 162.407 | 66.236 | 239.236 | 221.617 | 204.432 | 427.471 | 432.645 | 391.620 | 327.668 | 1.858.000 |
| Short-term debt | 122.442 | 68.198 | 87.254 | 108.396 | 198.874 | 134.052 | 163.999 | 176.604 | 336.956 | 324.842 | 500.175 | 694.243 | 668.000 |
| Total debt | 251.872 | 181.096 | 183.211 | 189.599 | 265.110 | 373.288 | 385.616 | 381.036 | 764.427 | 757.487 | 891.795 | 1.021.911 | 2.526.000 |
EBITDA margin
89.9%
This company
15.8%
Market median
+469% vs market
20132025
Equity ratio
46.5%
This company
38.2%
Market median
+22% vs market
20132025
Return on equity
73.8%
This company
18.4%
Market median
+301% vs market
20132025
Net profit margin
61.8%
This company
8.1%
Market median
+663% vs market
20132025
Asset turnover
0.56×
This company
1.12×
Market median
-50% vs market
20132025
Debt / equity
1.15×
This company
0.62×
Market median
-85% vs market
20132025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
- Annual report 2020Filed via CVR / Virk · Period 2019-05-01 – 2020-04-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-04-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
HP Management | Management | 2023 | — | — |
ET | Audit | 1991 | — | — |
CC Management | Management | 2025 | — | — |
OI Management | Management | 2006 | — | — |
RG Management | Management | 2011 | — | — |
PE Management | Management | 1991 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2002 | — | — | |
| Board of Directors | 1991 | — | — | |
| Board of Directors | 1991 | — | — | |
| Chairman | 2019 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 1991 | — | — | |
| Board of Directors | 1991 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 1991 | — | — | |
| Board of Directors | 1991 | — | — | |
| Chairman | 2002 | — | — | |
| Chairman | 1991 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
PHARMACOSMOS HOLDING A/S | Company | 100.0% | 100.0% | 2005 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medicosmos Holding A/S
PHARMACOSMOS A/S Board members of PHARMACOSMOS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tobias Sidelmann Christensen | Chief Executive Officer | 0 companies |
| Henrik Parker | Management | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Claes Christian Strøm | Management | 0 companies |
| Odd Inge Vaage-Nilsen | Management | 0 companies |
| Robert Guglielmetti | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Tommy Pedersen | Board of Directors | 0 companies |
| Ulf Svejgaard Poulsen | Board of Directors | 0 companies |
| Lars Christensen | Board of Directors | 0 companies |
| Jacob Tolstrup | Chairman | 0 companies |
| Martin Holst Lange | Board of Directors | 0 companies |
| Henry Marinus Christensen | Chairman | 0 companies |
| Lars Juul Peitersen | Board of Directors | 0 companies |
| Lars Green | Board of Directors | 0 companies |
| Milena Jordanova Olsen | Board of Directors | 0 companies |
| Annemarie Sidelmann | Chairman | 0 companies |
| Torkil Christensen | Board of Directors | 0 companies |
| Axel Kierkegaard | Chairman | 0 companies |
| Susanne Saul Stakemann | Chairman | 0 companies |